Francis Lo - 11 Mar 2026 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role
Chief People Officer
Signature
/s/ Francis Lo by Kyle Piskel, Attorney-in-Fact
Issuer symbol
ADPT
Transactions as of
11 Mar 2026
Net transactions value
-$430,749
Form type
4
Filing time
13 Mar 2026, 21:02:03 UTC
Previous filing
09 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LO FRANCIS Chief People Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVENUE EAST, SEATTLE /s/ Francis Lo by Kyle Piskel, Attorney-in-Fact 13 Mar 2026 0001780660

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADPT Common Stock Sale $430,749 -30,593 -9.5% $14.08 291,374 11 Mar 2026 Direct F1, F2
holding ADPT Common Stock 2,500 11 Mar 2026 By You Jin Lee (spouse)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
F2 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.81 to $14.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.